Archimedes Bio-degradable Bile Duct Stent Study

  • STATUS
    Recruiting
  • days left to enroll
    40
  • participants needed
    53
  • sponsor
    Nottingham University Hospitals NHS Trust
Updated on 1 April 2021

Summary

This is a prospective observational cohort study to assess the utility of bio-degradable bile duct stent in the drainage of bile duct. All consecutive patients who will undergo ERCP procedure for bile leaks and patients with bile duct stones and intact gall bladder will be recruited to the study. The planned sample size is 53 and patients will be followed up for 180 days. The primary objective is to assess the utility of biodegradable bile duct plastic stents in the drainage of bile duct.

The secondary Secondary objectives are To assess

  1. Technical success of biodegradable stents
  2. Complications
  3. Patient related cost savings (Time off work, travel time for the patient)
  4. Hospital related cost savings (Repeat procedure costs, follow up appointments)

Description

This is a Multi-centre prospective observational cohort study assessing biodegradable stents in the drainage of bile duct. The participating organisations are Nottingham university hospitals NHS trust which is the host and sponsor of this study, University college London Hospitals NHS foundation trust and Leeds teaching hospitals NHS trust.

The population studied will be patients who need temporary bile duct stent insertion for bile leak and patients who had ERCP for removal of CBD stones and have stones either in the neck of gall bladder or cystic duct and awaiting cholecystectomy. These are the group of patients who may not benefit from a repeat endoscopic procedure to remove the stent. As the target population is rare, all consecutive patients with above condition will be recruited to the study.

All patients who are referred for ERCP will be screened to see if they meet the eligibility criteria to participate in the study. The patient information sheet (PIS) will be sent to the patient along with the endoscopy appointment. The pateints will be consented both for the procedure and the study on the day of the procedure. Then the patients will have the procedure in their respective endoscopic units. All ERCP procedures will be done either by an accredited endoscopist or by a trainee under the close supervision of the accredited endoscopist.

Once the patients have their treatment, the patients will be observed for four hours for complications. Then discharged home if they are well and do not have any symptoms such as pain, persistent low blood pressure (defined as systolic less than 100) and have recovered from the effects of sedation. If at all the pateints develop any of the above symptoms, then the patients will be admitted for an overnight observation. The patients will have a telephone consultation by research specialist nurses the next day to assess if they have symptoms such as abdominal pain, vomiting, vomiting of blood and dark tarry stools. If the patients develop any of these symptoms, the patients will be assessed in the bio-medical research centre or respective inpatient facility in relevant centres. The patients will then have a blood test including full blood count, liver function and renal function. Amylase will be done only if they complain of abdominal pain as a proportion of patients will have hyper-amylasaemia following ERCP. The patients will also receive a telephone consultation (Research nurse) on day 7 post procedure to assess if they have any of the above symptoms. A quality of life questionnaire will be completed at this stage.

The investigators will be using slow degrading stents so, therefore the patients will have an abdominal x-ray 90 days after the procedure and if the stent is not visible on abdominal X-ray then they would have completed the study. As recent studies have shown that the stent appear partially degraded in some patients, if the stent is visible on x-ray then the patients will have one more follow up visit with an abdominal x-ray at 180 days. The invetstigator will not remove the stent as the stent would have partially degraded and would have lost its tensile strength.

Almost all bile leaks are inpatients so the resolution of bile leak will be assessed while they are inpatients. The resolution of bile leak is defined as no output from the external drain that was inserted through the skin under radiological guidance. For bile duct stones it is the prevention of bile duct infection (Cholangitis). The pateints will have telephone consultations on days 1,30,60,90 and 180 to asses if they have symptoms such as abdominal pain, jaundice. A quality of life questionnaire (EQ-5D-5L) will be completed at all these visits. Once the patient completes all of the above, they will have completed the study.

Details
Condition Bile Leak, bile leaks, Common Bile Duct Stone With Chronic Cholecystitis
Treatment ERCP and insertion ofBio-degradable bile duct stent
Clinical Study IdentifierNCT04477005
SponsorNottingham University Hospitals NHS Trust
Last Modified on1 April 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Participant is willing and able to give informed consent for participation in the study
Male or Female, aged 18 years or above
Patients who have an indication for ERCP
Patients who have bile leak either post cholecystectomy or liver resection
Patients who are on the waiting list for cholecystectomy for gall stones but have bile duct stones and listed for removal of bile duct stones
Able (in the Investigators opinion) and willing to comply with all study requirements
Willing to allow his or her General Practitioner and consultant, if appropriate, to be notified of participation in the study

Exclusion Criteria

Female participants who is pregnant, lactating or planning pregnancy during the course of the study
Patients who are unable to consent for the study
Participant who is terminally ill
Patients who come for ERCP and routine stent change
Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note